Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
View Patent ↗Glucagon receptor antagonist compounds are disclosed which are of long duration of action. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.
1. A compound which is:
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 which is:
or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.
4. A method of treating type 2 diabetes mellitus in a mammalian patient in need of such treatment comprising administering to said patient the compound of claim 1 or a pharmaceutically acceptable salt thereof in an amount that is effective to treat said type 2 diabetes mellitus.
5. A method of treating hyperglycemia, diabetes or insulin resistance in a mammalian patient in need of such treatment which comprises administering to said patient an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof.
6. A method of treating a condition selected from the group consisting of: (1) hyperglycemia, (2) low glucose tolerance, (3) insulin resistance, (4) retinopathy, (5) nephropathy, (6) neuropathy, (7) Syndrome X, and other conditions and disorders where insulin resistance is a component, in a mammalian patient in need of such treatment, comprising administering to the patient the compound of claim 1 or a pharmaceutically acceptable salt thereof in an amount that is effective to treat said condition.
7. A method of treating a condition selected from the group consisting of hypercholesterolemia, atherosclerosis, low HDL levels, high LDL levels, hyperlipidemia, hypertriglyceridemia and dyslipidemia, in a mammalian patient in need of such treatment, comprising administering to the patient the compound of claim 1 or a pharmaceutically acceptable salt thereof in combination with a HMG-CoA reductase inhibitor.
8. A method of treating a condition selected from the group consisting of hypercholesterolemia, atherosclerosis, low HDL levels, high LDL levels, hyperlipidemia, hypertriglyceridemia and dyslipidemia, in a mammalian patient in need of such treatment, comprising administering to the patient the compound of claim 1 or a pharmaceutically acceptable salt thereof in combination with a cholesterol absorption inhibitor.
9. The method of claim 7 wherein the cholesterol absorption inhibitor compound is:
or a pharmaceutically acceptable salt thereof.